Page last updated: 2024-10-30

losartan and Aortic Valve Insufficiency

losartan has been researched along with Aortic Valve Insufficiency in 3 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Aortic Valve Insufficiency: Pathological condition characterized by the backflow of blood from the ASCENDING AORTA back into the LEFT VENTRICLE, leading to regurgitation. It is caused by diseases of the AORTIC VALVE or its surrounding tissue (aortic root).

Research Excerpts

Excerpt	Relevance	Reference
"Nifedipine-treated animals displayed hemodynamics, LV dilatation, hypertrophy, and loss of function similar to those of the untreated group."	1.35	Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation. ( Arsenault, M; Beaudoin, J; Champetier, S; Couet, J; Lachance, D; Plante, E; Roussel, E, 2009)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Flyer, JN	1
Sleeper, LA	2
Colan, SD	2
Singh, MN	1
Lacro, RV	2
Dietz, HC	1
Yetman, AT	1
Bradley, TJ	1
Pearson, GD	1
Selamet Tierney, ES	1
Levine, JC	1
Atz, AM	1
Benson, DW	1
Braverman, AC	1
Chen, S	1
De Backer, J	1
Gelb, BD	1
Grossfeld, PD	1
Klein, GL	1
Lai, WW	1
Liou, A	1
Loeys, BL	1
Markham, LW	1
Olson, AK	1
Paridon, SM	1
Pemberton, VL	1
Pierpont, ME	1
Pyeritz, RE	1
Radojewski, E	1
Roman, MJ	1
Sharkey, AM	1
Stylianou, MP	1
Wechsler, SB	1
Young, LT	1
Mahony, L	1
Plante, E	1
Lachance, D	1
Beaudoin, J	1
Champetier, S	1
Roussel, E	1
Arsenault, M	1
Couet, J	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)[NCT00429364]			Phase 3	608 participants (Actual)	Interventional	2007-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Absolute Dimension

The rate of change in the absolute dimension of the aortic root over a 3-year period following randomization (NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	cm/year (Least Squares Mean)
Atenolol	0.069
Losartan	0.075

Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Body-surface-area-adjusted Z-score

The rate of aortic root enlargement, expressed as the annual change in the maximum aortic-root-diameter z score indexed to body-surface area over a 3-year period following randomization (NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	z-score/year (Least Squares Mean)
Atenolol	-0.139
Losartan	-0.107

Annual Rate of Change in Aortic-annulus-diameter Z Score, Adjusted by Body-surface Area

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	z-score/year (Least Squares Mean)
Atenolol	-0.279
Losartan	-0.175

Annual Rate of Change in Arm Span to Height Ratio

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	1/year (Least Squares Mean)
Atenolol	0.001
Losartan	0.001

Annual Rate of Change in Ascending-aorta-diameter Z Score, Adjusted by Body-surface-area.

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	z-score/year (Least Squares Mean)
Atenolol	-0.140
Losartan	-0.114

Annual Rate of Change in Body Mass Index

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	kg/m^2 per year (Least Squares Mean)
Atenolol	0.063
Losartan	0.076

Annual Rate of Change in Body Mass Index for Age Z-score

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	z-score/year (Least Squares Mean)
Atenolol	0.007
Losartan	0.021

Annual Rate of Change in Height

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	cm/year (Least Squares Mean)
Atenolol	0.822
Losartan	0.935

Annual Rate of Change in Height-for-age Z-score

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	z-score/year (Least Squares Mean)
Atenolol	0.046
Losartan	0.019

Annual Rate of Change in the Absolute Diameter of the Aortic Annulus

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	cm/year (Least Squares Mean)
Atenolol	0.015
Losartan	0.030

Annual Rate of Change in the Absolute Diameter of the Ascending Aorta

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	cm/year (Least Squares Mean)
Atenolol	0.039
Losartan	0.044

Annual Rate of Change in Total Aortic Proximal Regurgitant Jet Area Indexed to Body-surface-area

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	(mm^2/m^2)/year (Least Squares Mean)
Atenolol	0.005
Losartan	0.001

Annual Rate of Change in Upper to Lower Segment Ratio

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	1/year (Least Squares Mean)
Atenolol	-0.014
Losartan	-0.015

Annual Rate of Change in Weight

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	kg/year (Least Squares Mean)
Atenolol	0.239
Losartan	0.229

Annual Rate of Change in Weight-for-age Z-score

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	z-score/year (Least Squares Mean)
Atenolol	0.011
Losartan	0.019

Annual Rate of Change in Weight-for-height Z-score

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	z-score/year (Least Squares Mean)
Atenolol	-0.001
Losartan	-0.157

Event Rate of Aortic Dissection.

Percentage of participants who had aortic dissection over a 3-year period following randomization. (NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	Percentage of participants (Number)
Atenolol	0
Losartan	0.7

Event Rate of Aortic-Root Surgery

Percentage of participants who had aortic-root surgery over a 3-year period following randomization. (NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	Percentage of participants (Number)
Atenolol	3.4
Losartan	6.0

Event Rate of Death

Percentage of participants who died over a 3-year period following randomization. (NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	Percentage of participants (Number)
Atenolol	0
Losartan	0.3

Event Rate of the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.

Percentage of participants who had aortic dissection, aortic-root surgery or death over a 3-year period following randomization (NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	Percentage of participants (Number)
Atenolol	3.4
Losartan	6.4

Number of Death.

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	participants (Number)
Atenolol	0
Losartan	1

Number of Participants With Aortic Dissection.

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	participants (Number)
Atenolol	0
Losartan	2

Number of Participants With Aortic-root Surgery.

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	participants (Number)
Atenolol	10
Losartan	18

Number of Participants With the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.

(NCT00429364)
Timeframe: Up to 3 years following randomization.

Intervention	participants (Number)
Atenolol	10
Losartan	19

Adverse Drug Reactions Reported at the Baseline Visit

(NCT00429364)
Timeframe: At baseline

Intervention	participants (Number)
	Headache, any severity	Headache, bothersome	Fatigue, any severity	Fatigue, bothersome	Mood alterations, any severity	Mood alterations, bothersome	Behavior changes, any severity	Behavior changes, bothersome	Insomnia, any severity	Insomnia, bothersome	Nightmares, any severity	Nightmares, bothersome	Dizziness with standing, any severity	Dizziness with standing, bothersome	Dizziness - other, any severity	Dizziness - other, bothersome	Fainting with loss of consciousness, any severity	Fainting with loss of consciousness, bothersome	Palpitations, any severity	Palpitations, bothersome	Chest pain, any severity	Chest pain, bothersome	Dyspnea, any severity	Dyspnea, bothersome	Wheezing, any severity	Wheezing, bothersome	Upper respiratory/Nasal congestion, any severity	Upper respiratory/Nasal congestion, bothersome	Cough, any severity	Cough, bothersome	Dysgeusia, any severity	Dysgeusia, bothersome	Stomach pain/Indigestion, any severity	Stomach pain/Indigestion, bothersome	Nausea, any severity	Nausea, bothersome	Vomiting, any severity	Vomiting, bothersome	Diarrhea, any severity	Diarrhea, bothersome	Constipation, any severity	Constipation, bothersome	Vascular (hands, feet), any severity	Vascular (hands, feet), bothersome	Muscle pain or Cramps, any severity	Muscle pain or Cramps, bothersome	Back pain, any severity	Back pain, bothersome	Periorbital edema, any severity	Periorbital edema, bothersome	Pedal edema, any severity	Pedal edema, bothersome	Other, any severity	Other, bothersome
Atenolol	112	10	84	0	54	7	21	2	60	2	52	2	60	0	25	0	5	5	60	0	54	1	43	3	15	2	106	0	47	1	10	0	47	0	30	1	23	0	35	1	44	0	35	0	59	2	60	3	13	0	2	0	21	3
Losartan	114	10	105	0	49	3	23	1	61	2	53	3	58	2	27	1	9	9	53	0	58	5	38	0	14	1	117	2	59	0	3	0	61	1	35	0	23	0	43	1	35	0	34	1	58	4	67	2	15	0	3	0	16	1

Adverse Drug Reactions Reported During Routine Follow-up Surveillance

(NCT00429364)
Timeframe: From 6 months to 3 years following randomization.

Intervention	participants (Number)
	Headache, any severity	Headache, bothersome	Fatigue, any severity	Fatigue, bothersome	Mood alterations, any severity	Mood alterations, bothersome	Behavior changes, any severity	Behavior changes, bothersome	Insomnia, any severity	Insomnia, bothersome	Nightmares, any severity	Nightmares, bothersome	Dizziness with standing, any severity	Dizziness with standing, bothersome	Dizziness - other, any severity	Dizziness - other, bothersome	Fainting with loss of consciousness, any severity	Fainting with loss of consciousness, bothersome	Palpitations, any severity	Palpitations, bothersome	Chest pain, any severity	Chest pain, bothersome	Dyspnea, any severity	Dyspnea, bothersome	Wheezing, any severity	Wheezing, bothersome	Upper respiratory/Nasal congestion, any severity	Upper respiratory/Nasal congestion, bothersome	Cough, any severity	Cough, bothersome	Dysgeusia, any severity	Dysgeusia, bothersome	Stomach pain/Indigestion, any severity	Stomach pain/Indigestion, bothersome	Nausea, any severity	Nausea, bothersome	Vomiting, any severity	Vomiting, bothersome	Diarrhea, any severity	Diarrhea, bothersome	Constipation, any severity	Constipation, bothersome	Vascular (hands, feet), any severity	Vascular (hands, feet), bothersome	Muscle pain or Cramps, any severity	Muscle pain or Cramps, bothersome	Back pain, any severity	Back pain, bothersome	Periorbital edema, any severity	Periorbital edema, bothersome	Pedal edema, any severity	Pedal edema, bothersome	Other, any severity	Other, bothersome
Atenolol	202	27	152	7	89	13	51	5	108	6	100	7	119	6	60	2	21	21	86	0	114	14	75	1	36	2	188	3	117	1	29	0	119	2	99	0	81	1	94	1	77	1	73	0	148	6	137	5	22	0	6	0	105	10
Losartan	208	20	153	5	86	13	46	8	107	4	94	4	105	0	61	0	16	16	101	0	106	1	72	3	32	5	186	3	113	1	16	0	121	8	78	0	75	2	90	3	66	0	66	0	124	7	134	8	27	1	5	0	108	12

Trials

1 trial available for losartan and Aortic Valve Insufficiency

Article	Year
Atenolol versus losartan in children and young adults with Marfan's syndrome. The New England journal of medicine, 2014, Nov-27, Volume: 371, Issue:22 Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Aneurysm;	2014

Other Studies

2 other studies available for losartan and Aortic Valve Insufficiency

Article	Year
Effect of Losartan or Atenolol on Children and Young Adults With Bicuspid Aortic Valve and Dilated Aorta. The American journal of cardiology, 2021, 04-01, Volume: 144 Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers;	2021
Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation. Circulation. Heart failure, 2009, Volume: 2, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic V	2009